



March 9, 2018

Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Dicerna Pharmaceuticals, Inc.](#) (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will provide a corporate overview at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium on Friday, March 16, 2018 at 4:30 p.m. local time. The conference will be held March 16-17, 2018 at The InterContinental Hotel Hangzhou.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20180309005084/en/>

Investor:

Rx Communications Group
Paula Schwartz, 917-322-2216
pschwartz@rxir.com

or

Media:

SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Source: Dicerna Pharmaceuticals, Inc.

News Provided by Acquire Media